CORE 2: Biospecimen

核心 2：生物样本

• 批准号: 10188454
• 负责人: Klaus Busam
• 金额: $ 15.27万
• 依托单位: UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10188454
• 关键词: Aliquot; Archives; Area; Biological Assay; Cell Survival; Cells; Clinical Research; Collection; Common Neoplasm; DNA; Data; Databases; Dermatopathology; Diagnosis; Diagnostic; Disease Management; Documentation; Ensure; Freezing; Genetic; Goals; Heterogeneity; Histopathology; Hospitals; Individual; Infrastructure; Institution; Investigation; Laboratories; Lead; Methods; Methylation; Mitotic; Molecular; Molecular Biology; Molecular Epidemiology; Mutation; Necrosis; Nevus; Nucleic Acids; Pathologic; Pathology; Phase; Play; Population; Preparation; Principal Investigator; Program Research Project Grants; RNA; Research; Research Personnel; Research Project Grants; Role; Sampling; Solar elastosis; Specimen; Specimen Handling; System; Testing; Thick; Tissue Sample; Tissues; Translational Research; Tumor Tissue; Tumor-Infiltrating Lymphocytes; Ulcer; Work; base; clinical biomarkers; data repository; digital; epidemiology study; experience; experimental study; genomic data; melanoma; melanoma biomarkers; member; molecular marker; neoplastic cell; prognostic; programs; sample collection; success; tumor

CORE 2 – SUMMARY The Biospecimen Core (Core 2) will play a central role by providing pathology and biospecimens support, and appropriate infrastructure to the P01. Its expertise in pathology, molecular biology, and molecular epidemiology will contribute to the validity of the proposed study as it will provide centralized histopathologic review and the correct diagnosis of all tumor samples, and ensure utilization of the appropriate tissue. This core will provide a systematic co-extraction of DNA and RNA from unique tumor cell lysates which will ensure proper integration of findings across different research aims and add to the validity of the P01 results. The core will also conduct a systematic quality assessment of samples and derived data to ensure experimental success of the individual research projects. This core will distribute specimens to Program Projects 1-3, and related data to Core 1 where it will be made available to all projects and cores. The core will utilize the MSK Institutional Pathology Core and Clinical Research Database (CRDB). The latter will help centralize the repository of data and provide an integrated specimen tracking system. The Biospecimen Core will be led by Dr. Klaus Busam, leader of Dermatopathology at MSK. He is recognized for his experience with melanoma diagnostic issues and has extensive experience in managing archival and frozen tissue samples. He will lead the diagnostic aspects of the project, and will ensure the utilization of high quality banked melanomas through assessment of cell heterogeneity and purity. Dr. Orlow will be the co-leader of the Biospecimen Core. She directs the Molecular Epidemiology Laboratory at MSK and has a wealth of experience in the handling and testing of different types of tissues, and in the banking and distribution of specimens for various hospital based and large multicenter epidemiologic studies. She will oversee and coordinate the collection, processing, and testing of specimens, data entry, and re-distribution of specimens and data for the P01. Drs. Busam and Orlow are co-Principal Investigators of the Institutional Melanoma Disease Management Team. They have collaborated with the overall leaders and several investigators of this Program Project for many years. Together, they will oversee the administrative aspects of the core. The objectives of the Biospecimen Core (Core 2) are to: (1) assemble the collection of specimens and establish relevant histopathologic, immunohistochemical and molecular data relevant to the investigation of melanoma tumors and host genetics; (2) provide expert review of melanoma tumors with documentation of tumor diagnosis, histopathologic prognostic features, volume, viability and purity of available tumor issue; (3) perform systematic extraction and characterization of nucleic acids; (4) provide RNA and DNA sample sets and associate sample annotation as needed to the individual research projects. As part of this objective, the Biospecimen Core will procure specimens for mutational testing with the MSK-IMPACTTM assay and digital PCR.

核心 2 – 总结 生物样本核心（核心 2）将通过提供病理学和生物样本支持发挥核心作用，并且 其在病理学、分子生物学和分子流行病学方面的专业知识。 将有助于拟议研究的有效性，因为它将提供集中的组织病理学审查和 正确诊断所有肿瘤样本，并确保利用适当的组织。 从独特的肿瘤细胞裂解物中系统地共提取 DNA 和 RNA，确保正确整合 该核心还将开展跨不同研究目标的调查结果并增加 P01 结果的有效性。 对样本和派生数据进行系统的质量评估，以确保个体实验的成功 该核心将向计划项目 1-3 分发样本，并向核心 1 分发相关数据。 它将提供给所有项目和核心，核心将利用 MSK 机构病理学。 核心和临床研究数据库（CRDB）将有助于集中数据存储库并提供服务。 集成的样本跟踪系统。 生物样本核心将由 MSK 皮肤病理学负责人 Klaus Busam 博士领导。 表彰他在黑色素瘤诊断问题方面的经验，并在管理档案和 他将领导该项目的诊断方面，并确保高利用率。 Orlow 博士将担任联合领导者，通过评估细胞异质性和纯度来储存黑色素瘤。 她是 MSK 斯隆分子流行病学实验室的负责人，拥有丰富的经验。 在处理和测试不同类型的组织以及储存和分配组织方面拥有丰富的经验 她将监督和收集用于各种医院和大型多中心流行病学研究的样本。 协调样本的收集、处理和测试、数据输入和样本的重新分配 Busam 和 Orlow 博士是黑色素瘤机构的联合首席研究员。 他们与该项目的总体领导和几位研究人员进行了合作。 他们将共同监督核心的管理工作多年。 生物样本核心（核心 2）的目标是：(1) 收集样本并 建立与研究相关的组织病理学、免疫组织化学和分子数据 黑色素瘤和宿主遗传学；(2) 提供黑色素瘤的专家评审以及以下文件： 肿瘤诊断、组织病理学预后特征、可用肿瘤问题的体积、活力和纯度； 进行核酸的系统提取和表征；(4) 提供 RNA 和 DNA 样本集以及 根据需要将样本注释与各个研究项目相关联。 Biospecimen Core 将采购样本用于使用 MSK-IMPACTTM 检测和数字化进行突变测试 PCR。